Cellino

Cellino Appoints Chris Gibson to Board of Directors

CAMBRIDGE, Mass. – Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. “The intersection of deep technology, biology, and medicine presents unprecedented opportunities and challenges. We are thrilled to have Chris’ experience on our board to provide Cellino with a perspective that is both visionary and deeply … Continue reading Cellino Appoints Chris Gibson to Board of Directors

enGene

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

October 21, 2024 – BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of … Continue reading enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Vianautis

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who has been stepping down from her role. Dr Adi Hoess brings a wealth of experience to ViaNautis, having previously served as CEO of Nasdaq-listed German … Continue reading ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

axolbio

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, October 2024: Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell … Continue reading Axol Bioscience acquires Phenocell to advance human disease models

Seaport Therapeutics

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 … Continue reading Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round